Skip to main content

Table 4 Receptor discordance

From: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

ER
 Concordant 105 (79.6%)
 Discordant 27 (20.4%)
 Gain 6 (4.5%)
 Loss 21 (15.9%)
PR
 Concordant 82 (62.1%)
 Discordant 50 (37.8%)
 Gain 6 (4.5%)
 Loss 44 (33.2%)
HER2
 Concordant 128 (97%)
 Discordant 4 (3%)
 Gain 2 (1.5%)
 Loss 2 (1.5%)
 Subtype N (%)
 Concordant 101 (76.5%)
 Discordant 31 (23.5%)